There are basically two differing schools of thought here:
1: Shareholders will receive nothing as the company has been dissolved. Many posters/shareholders here fall into this category based on the words used in the filings, and view of how bankruptcy proceedings typically transpire.
2: Shareholders will become whole with some sort of distribution thanks to the agreed on Milestone Payments included in the sale document to Taran & that we may receive shares in Taran. Jay is the most vocal believer in this outcome (though I'm sure not alone), and it is based on belief in management and experience with similar situations occurring with said management.
Which route you believe in is entirely up to you. Hope this helps explain things more simply.
For your further consideration, Diego, "...based on the words used in the filings..." we have the following.
"2. Milestone Payments The Purchaser, the Foreign Subsidiary, and any other entity that is an Affiliate of the Purchaser or Foreign Subsidiary that acquires any of the Acquired Assets (the “Regulatory Milestone Parties” which Regulatory Milestone Party shall include any entity that merges with or enters into a joint venture with any of the Regulatory Milestone Parties), may be obligated to pay to the Debtor or its successor or assignee (including, but not limited to, statutory trustees, plan trustees, plan administrators, litigation trustees, and liquidating trustees) certain contingent payments (the “Milestone Payments”) in consideration for the Acquired Assets upon achievement of certain development and commercial milestone events..."
Now, this may not be, "...how bankruptcy proceedings typically transpire." (Just messin' with you, SG44), but Durrant and Dale are not typical executives treading in these murky waters. They were hugely successful with the recall of the loaned shares of Kalobios. No, this was not strictly Shkreli. He appointed Dale and Durrant to the KBIO Board, and Durrant was in the CEO's chair while it was still warm after Shrkreli's departure. They, alone, navigated through KBIO's bankruptcy, and kept the shareholders whole coming out of that bankruptcy, achieving the biggest short squeeze that has yet to be surpassed...that is, until Humanigen/Taran does that, as we will.
Bottom line is, I think Humanigen/Taran's lenzilumab is what enhanced Novavax's covid vaccine to the point that Sanofi wants to use the NVAX vaccine with their flu vaccine. Doubtless, Sanofi, like Gracell and Mayo Clinic, and like our PREACH-M and RATinG trial sponsors, is also eager to use lenz with their cancer treatment platform. I fully expect that Filip Dubovsky will join us, and use his extensive Product Development experience to help us to achieve what he helped Novavax to achieve.
Market Data 
Markets 
AI
